A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are to compare the anti-tumor activity as measured by
Progression Free Survival (PFS) and tolerability of Sorafenib in combination with Paclitaxel
and Carboplatin versus Paclitaxel and Carboplatin in combination with placebo in subjects
with unresectable Stage III or Stage IV melanoma who progressed after receiving only one
prior therapy containing Dacarbazine (DTIC) or Temozolomide (TMZ).